Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Science 6 April 2001:
Vol. 292. no. 5514, pp. 24 - 25
DOI: 10.1126/science.292.5514.24
Prev | Table of Contents | Next

News of the Week

AIDS RESEARCH:
Merck Reemerges With a Bold AIDS Vaccine Effort

Jon Cohen

KEYSTONE, COLORADO--Over the past few years, scientists from Merck & Co. have quietly built an AIDS vaccine research program that has fundamentally altered the landscape of this beleaguered field. At a scientific meeting here this week, Merck researchers described a comparison of various AIDS vaccine approaches in more than 100 monkeys. What most dazzled researchers here is the sheer scale of the company's AIDS vaccine effort, an endeavor that has attracted scant interest from other big pharmaceutical companies.

Read the Full Text


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Assessment of a Combined, Adenovirus-Mediated Oncolytic and Immunostimulatory Tumor Therapy.
K. M. Bernt, S. Ni, A.-T. Tieu, and A. Lieber (2005)
Cancer Res. 65, 4343-4352
   Abstract »    Full Text »    PDF »
Gene Vaccines.
I. K. Srivastava and M. A. Liu (2003)
Ann Intern Med 138, 550-559
   Abstract »    Full Text »    PDF »
Vaccines and Vaccination.
G. Ada (2001)
N. Engl. J. Med. 345, 1042-1053
   Full Text »    PDF »


To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)